EGFR and cancer: Complex rearrangements identified in at least two samples spanned the established TGCT oncogenes KRAS, MYC, EGFR, and members of signalling pathways commonly dysregulated in cancers including WNT (SOX2), RTK (PDGFRA), and the p53 pathway inhibitors, CDK4/6 and MDM2 (Supplementary Data 5).